Login
$IRON
$76.59 +$0.00 (0.0%) After hours

Company Executives

Officer Age In this role 2025 pay Source
John Quisel Also a director
Chief Executive Officer
Title from the Form 4 dated Sep 15, 2026
54 Not stated $9,986,626
Jean Franchi
Chief Financial Officer
59 Since 2024
2 years
$4,169,143
Jonathan Yu, M.B.A.
Chief Operating Officer
45 Since 2024
2 years
$3,485,203
Pamela Stephenson, M.P.H.
Chief Commercial Officer
58 Since 2024
2 years
$4,162,263
William Savage, M.D., Ph.D.
Chief Medical Officer
52 Since 2021
5 years
$3,510,483
Rahul Khara, Pharm.D., J.D.
Chief Legal Officer
Title from the Form 4 dated Aug 6, 2026
44 Not stated Not reported
William Jacob Savage
Chief Medical Officer
Title from the Form 4 dated Nov 10, 2026
Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Independent
1 of 2
stated in the proxy; 6 not stated
Average tenure
5.6 years
from year joined
CEO also chairs the board
No
Donald Nicholson
Director Age On board Independent Committees Other public boards 2025 pay Source
Donald Nicholson
68 2019
7 years
Independent
Compensation Committee · Chair
None stated Not stated
John Quisel
54 2020
6 years
Not independent None stated Gossamer Bio, Inc. (Nasdaq: GOSS) Paid as CEO
William White
53 2020
6 years
Not stated
Audit Committee · Chair
None stated $478,177
Nadim Ahmed
58 2025
1 year
Not stated
Commercial Committee
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) $985,609
Kevin Bitterman
49 2017
9 years
Not stated
Compensation Committee Nominating and Corporate Governance Committee · Chair
None stated Not stated
Mark Chin
44 2021
5 years
Not stated
Audit Committee Commercial Committee
None stated $470,677
Georges Gemayel
65 2022
4 years
Not stated
Compensation Committee Commercial Committee · Chair
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) Not stated
Liam Ratcliffe
62 2019
7 years
Not stated
Audit Committee Nominating and Corporate Governance Committee
Upstream Bio (Nasdaq: UPB), OnKure Therapeutics, Inc. (Nasdaq: OKUR) Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 28, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support